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Objective: The objective was to identify whether repeat positron emission tomography scan after neoadjuvant
chemoradiotherapy in patients with esophageal cancer predicted a complete response.
Methods:A retrospective study using a prospective database was performed. Patients had esophageal cancer and
underwent neoadjuvant chemoradiotherapy, an initial and repeat positron emission tomography, endoscopic ul-
trasound with fine-needle aspiration (at the same institution), and Ivor Lewis esophagogastrectomy with lymph
node resection.
Results: There were 221 patients who underwent Ivor Lewis, 86 of whom had their initial and repeat positron
emission tomography scans performed at the same center. Of these, 37 patients (43%) were complete responders.
The median maximum standardized uptake value of esophageal cancer decreased by 72% in the 37 patients who
were complete responders, by 58% in the 31 patients who were partial responders, and by 37% in the 18 patients
who had a minimal pathologic response. When the maximum standardized uptake value decreased by more than
64%, the patient was likely to be a complete responder (P ¼ .003, area under the curve ¼ 0.75).
Conclusion: When initial and repeat positron emission tomography scans are performed at the same center at
least 30 days after the completion of preoperative chemoradiotherapy, the percent change in the maximum stan-
dardized uptake value is a predictor of the response to chemoradiotherapy by a patient with esophageal cancer.
When the maximum standardized uptake value decreases by 64% or more, it is likely that the patient is a complete
responder. These data may help guide neoadjuvant therapy and identify patients for a future randomized study
that compares observation with surgical resection in patients with esophageal cancer who appear to be complete
responders.
Cerfolio et al General Thoracic SurgeryIn 2007, an estimated 15,560 patients were diagnosed with
esophageal cancer and 13,940 deaths occurred from this in-
sidious disease.1 The 5-year survival is 50% to 80% for
stage I esophageal carcinoma, 30% to 40% for stage II
esophageal carcinoma, 10% to 30% for stage III esophageal
carcinoma, and 0% to 15% for stage IV esophageal carci-
noma.2-4 Patients are often offered preoperative chemoradio-
therapy before resection in an attempt to increase the 5-year
survivals. The treatment of esophageal cancer, as for most
solid-organ tumors, is dictated by the stage. However, the
clinical stage often does not accurately reflect the true path-
ologic stage. The best survivals after resection occur in pat-
ents who are ‘‘complete responders’’ and then undergo
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doi:10.1016/j.jtcvs.2008.11.016The Journal of Thoracic and Cesophageal resection. Neoadjuvant therapy may eradicate
micrometastatic disease and thus prevents future metastatic
recurrence. Some argue that these patients are best served
by surgery, and others argue that because these patients’
tumors are ‘‘all dead,’’ they can avoid the morbidity and
mortality of esophagogastrectomy. Although there are no
data to support this position, some physicians and patients
choose it. The idea of a randomized study of patients who
are believed to be complete responders to receive either sur-
gery or observation alone has been discussed. However, this
discussion is moot, because the only current reliable way to
determinewho truly is a complete responder is to operate and
resect the esophagus and perform pathologic confirmation.
The objective of this study was to evaluate the efficacy and
accuracy of repeat positron emission tomography (PET)
scans in predicting the pathologic response in both the
primary tumor and lymph nodes, and to determine who is
a complete responder before surgery.
MATERIAL AND METHODS
Patients
This is a retrospective cohort study of a prospective database from 1 gen-
eral thoracic surgeon in a university setting. The entry criteria for this study
mandated that patients have biopsy-proven esophageal cancer, an integrated
PET with computed tomography using fluorodeoxyglucose (integrated
PET/CT), and an endoscopic ultrasound with fine-needle aspirationardiovascular Surgery c Volume 137, Number 3 605
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SAbbreviations and Acronyms
CI ¼ confidence interval
EUS-FNA ¼ endoscopic ultrasound with fine
needle aspiration
FDG-PET ¼ 18F-fluorodeoxyglucose positron
emission tomography
maxSUV ¼ maximum standardized uptake value
NSCLC ¼ non–small cell lung cancer
(EUS-FNA) performed both initially and again after the completion of
neoadjuvant chemoradiotherapy at the same center. Patients underwent
radiation, most commonly using 50.4 Gy and concomitant chemotherapy
(most commonly using 5-flourouracil and cisplatinum), and then were re-
staged. Restaging took place no sooner than 30 days after the completion
of the radiotherapy.5 If patients had a repeat integrated PET/CT at a different
PET center or their maximum standardized uptake value (maxSUV) was not
reported, they were excluded from this study. Surgical resection had to oc-
cur no later than 40 days from the completion of the repeat PET scan. Other
exclusion criteria included age less than 19 years, the performance of any
type of esophagogastectremy other than an Ivor Lewis esophagogastrec-
tomy (thus mandated that all lymph nodes were removed to fully assess
the pathologic response), and incomplete course of neoadjuvant therapy.
The University of Alabama at Birmingham’s Institutional Review Board
approved this review of our prospective database. Patient consent was ob-
tained for the entry of their data in our prospective database but was waived
for this particular study.
Imaging
The PET scans performed at the University of Alabama at Birmingham
were conducted on an integrated PET-CT scanner (GE Discovery LS
PET-CT Scanner, Milwaukee, WI). Patients were asked to fast for 4 hours
and then subsequently received 555 MBq (15 mCi) of 18F-fluorodeoxy-
glucose (FDG) intravenously followed by PET after 1 hour. The maxSUV
was determined by drawing regions of interest on the attenuation-
corrected FDG-PET images around the primary tumor. It was then calcu-
lated by the software contained within the PET-CT scanner by a standard
formula.6
MaxSUV ¼ CðmCi=mlÞ
IDðmCiÞ
wðkgÞ
where C ¼ activity at a pixel within the tissue defined by region of interest
and ID ¼ injected dose per kilogram of patient’s body weight (w). The
maximum SUV within the selected regions of interest was used (max-
SUV). The percent change of the maxSUV was calculated by the following
formula:
maxSUV intitialmaxSUV final
maxSUV initial
3 100:
Patients who had PET scans performed at outside hospitals were included
in this trial if the scan was performed on a dedicated PET camera with bis-
muth germanate crystals. All patients were carefully staged, and biopsy of
all regional lymph nodes was performed via EUS-FNA as previously de-
scribed.7 However, if nodes were peritumoral, they were labeled malignant
or benign on the basis of their echogenicity criteria as assessed by EUS.
Only lymph nodes that were initially biopsied and proven to be malignant
were considered in the analysis of the change in the maxSUV of malignant
lymph nodes. Peritumoral nodes that were only judged as malignant or be-
nign on the basis of their echogenicity were not included in this analysis.
Biopsies were performed on all suspicious M1 metastatic lesions unless606 The Journal of Thoracic and Cardiovascular Sucancer was suspected in the bone or brain, where magnetic resonance imag-
ing was considered to be the gold standard.
Surgical Technique
All patients underwent Ivor Lewis esophagogastrectomy as previously
described, which includes the removal of lymph nodes from the celiac
axis and a thoracic lymphadenectomy.7,8 In brief, patients had a double-lu-
men endotracheal tube and an epidural placed (arterial lines and central lines
were rarely used). A midline laparotomy incision was performed; after ex-
ploration, to rule out metastatic disease, the stomach was mobilized via the
right gastroepiploic artery. The preferred treatment of the pylorus was injec-
tion of botulism toxin, which was used exclusively instead of other empty-
ing procedures for the latter part of this study.9 A feeding jejunostomy was
placed. Patients then underwent a right thoracotomy using amuscle-sparing,
rib-sparing, nerve-sparing technique,10-12 and the esophagus was mobilized
off the aorta and all regional lymph nodes were removed. A hand-sewn
anastomosis was performed 2 to 4 cm above the divided azygous vein.
Pathologic Analysis
The entire gastroesophageal junction was submitted at approximately
4-mm intervals. For the study, a single pathologist (T.S.W.) reevaluated
the sections to arrive at a percentage of nonviable tumor. The number of
sections considered to contain tumor included all sections with tumor, ul-
cer, scar and necrosis. The percent of nonviable tumor was defined as the
combined percentage of scar and necrosis. The percent of tumor was de-
rived from estimates of the amount of tumor in each section divided by
the amount of scar and necrosis in that section. If only 1 of a few sections
of ulcer or scar contained tumor, these were added to the total of scar and
necrosis. For example, 2 of 6 sections contain approximately 25% tumor.
The derived percent tumor would be 0.253 2/6 10% residual tumor. No
attempt was made to estimate closer than 5%, except for those with min-
imal residual disease. Patients with mixed tumors were labeled with squa-
mous cell or adenocarcinoma according to the predominant cellular type
seen. Complete pathologic response was defined as 1% or less of viable tu-
mor cells detected on pathologic review of the entire resected specimens.
Partial response was defined as 20% to 98% cellular death of cancer,
and minimal response was defined as less than 20% cellular death of cancer
in the resected specimen.
In addition, the response of metastatic, regional esophageal lymph nodes
that were initially biopsied and proven to be cancer was also assessed for
pathologic response. Each lymph node measuring less than 1 cm was eval-
uated as a single cross-section. For larger lymph nodes, additional cross-sec-
tions were evaluated, approximately 1/5 mm. Lymph nodes were labeled as
having recalcitrant disease, which was defined as having persistent cancer
cell despite the neoadjuvant therapy given, or they were defined as benign
or downstaged. This latter termwas defined as no evidence of anymalignant
cells in the once malignant lymph node. The pathologists were blinded to all
clinical, radiologic, and surgical findings.
Statistical Analysis
Analysis was conducted using SAS software 9.0 (SAS Corp, Cary, NC).
Continuous data are presented as medians, and categoric data are presented
as percentages. Fisher’s exact test or Pearson’s chi-square test was used to
assess categoric data, and theWilcoxon test was used to evaluate continuous
variables. After ensuring data were normally distributed and homoscedastic,
analysis of covariance was used to assess the relationship between the per-
cent change in maxSUV and pathologic response.Multiple linear regression
stepwise analysis was used to adjust for risk factors and to identify any vari-
ables that were independently associated with a complete response (age,
gender, final pathologic stage, dose of radiation, cell type, and type of neo-
adjuvant therapy). The highest combined sensitivity and specificity values
generated from the receiver operating characteristic curve that predicted
complete pathologic responders were identified.13rgery c March 2009
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There were 253 patients who underwent esophagogastrec-
tomy between January 1997 and June 2008 by 1 surgeon,
and 221 patients underwent an Ivor Lewis approach. The re-
maining 32 patients underwent a transhiatal total esophago-
gastrectomy with a gastric to pharyngeal anastomosis,
thoracoabdominal, or colonic interposition esophagogas-
trectomy and were not included in this study. Eighty-six of
these patients who underwent Ivor Lewis esophagogastrec-
tomy had an initial and repeat PET scan performed at the
same center and formed the cohort of this study. The patient
characteristics of these 86 patients are shown in Table 1. The
median number of lymph nodes that were removed were 24
(range, 14–41). Of these 86 patients, 37 (43%) were com-
plete responders and the median maxSUV of their esopha-
geal cancer decreased by 72% (range 20%–100%, 95%
confidence interval [CI] 68%–85%). The median maxSUV
decreased by 58% in the 31 patients who were partial re-
sponders (range 0%–99%; 95% CI, 52%–65%). The me-
dian maxSUV of the primary tumor decreased only 37% in
18 patients with a minimal response (range 38%–93%;
95% CI, 29%–43%). These differences were statistically
significant (P< .001).
There were 37 complete responders. Receiver operating
characteristic analysis, as shown in Figure 1, indicates that
when the maxSUV decreased by more than 64% (64% sen-
sitivity, 81% specificity), the patient was likely to be a com-
plete responder (P ¼ .003, area under the curve 0.75). Six
patients who had a decrease in their maxSUV of 64% or
greater of the primary tumor were not complete responders,
but tumors had more than 80% cellular death in all 6 pa-
tients, were pathologic node negative in all but 1 patient,
and were T1or T2N0M0 on final pathology in 4 of 6
patients. In addition to the percent change in the primary
tumor’s maxSUV, the percent change in the maxSUV of
biopsy-proven metastatic regional lymph nodes was also as-
sessed. Sixteen patients had 1 or more lymph nodes that had
its maxSUV recorded during their initial PET scan and had
biopsy-proven cancer. The median percent change in the
maxSUV of these lymph nodes in patients whose nodes
were initially malignant and then removed and were patho-
logically benign was 73% (11 patients). Five patients had
recalcitrant disease in a removed lymph node, and the me-
dian percent change in that node was only 45% (Table 2).
There was no statistically significant difference between
these groups (P ¼ .325).
DISCUSSION
The clinical importance of determining pathologic re-
sponse is well documented for patients with both non–small
cell lung cancer (NSCLC) and esophageal cancer. This in-
formation, if accurate, can be used to change chemothera-
peutic regimens, add radiotherapy, and help decide who is
best served by surgery. The concept of a prospective study
that would randomize patients with esophageal cancer who
appear to be complete responders to receive either surgery
or observation has been discussed at several national and in-
ternational meetings. However, the ability to accurately
make this determination before surgical resection is elusive.
Until now, surgical resection has been the only reliable man-
ner to discern who is a pathologic complete responder. This
TABLE 1. Patient characteristics (N ¼ 86)
Median age (range) y 60 (36–78)
Gender, male 64
Initial stage
Stage IIA (T2-3N0M0) 67
Stage IIB (T1-2N1M0) 13
Stage III (T3N1 or T4Nx) 6
Radiotherapy (median dose) 50.4 Gy
Median duration between last neoadjuvant treatment
and surgery (range)
39 d (34–56 d)
Tumor histology
Adenocarcinoma 53 (62%)
Squamous cell carcinoma 24 (28%)
Not otherwise specified/other 9 (10%)
Final pathology
pCR (T0N0M0) 37
Stage I (T1N0M0) 22
Stage IIA (T2-3N0M0) 11
Stage IIB (T1-2N1M0) 9
Stage III-IV (T3N1 or T4Nx), M1 7
pCR, Complete pathologic response.
FIGURE 1. Receiver operating characteristic curves of sensitivity (solid
lines) plotted against 100 minus specificity for FDG-PET. When the
maxSUV decreased by less than 64% (64% sensitivity, 81% specificity),
the patient was likely to be a complete responder (P ¼ .003, area under
the curve ¼ 0.75). Dashed line indicates 95% confidence interval.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 3 607
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PET scans have been performed at the same centers no
sooner than 30 days after the completion of the neoadjuvant
chemoradiotherapy) may be a reliable tool to provide such
information. In this retrospective study, we showed that
the percent change in the maxSUV was a sensitive predictor
of complete response. Moreover, the decrease in percent
change was less as the response of the tumor to the therapy
was less. Akhurst and colleagues in 200214 reported a retro-
spective series on 56 patients and found that FDG-PET after
induction therapy accurately detected residual viable pri-
mary tumor. Our 3 previous reports have demonstrated the
change in maxSUV of patients with NSCLC. Repeat PET
was shown to predict the response of mediastinal (N2)
lymph nodes in NSCLC in 2003,15 and in 200416 we showed
a near linear relationship between the percent of necrotic
lung cancer and the percent decrease in the maxSUV. How-
ever, Port and colleagues in 200417 showed that the change
in the maxSUV was not an accurate predictor of pathologic
response in patients with NSCLC. In that study though, Port
and colleagues did not specify that that the repeat PET was
performed at the same center as the initial PET. In 200518 we
showed the role that repeat PET and the change in maxSUV
(as well as repeat EUS-FNA) play in the restaging of patients
with esophageal cancer. Despite their early negative study
results on repeat PET in patients with lung cancer, Port
and colleagues19 in 2007 reported that a decrease in max-
SUV by 50% or more after induction therapy was signifi-
cantly associated with complete response or pathologic
downstaging.
The maxSUV remains a controversial part of PET scan re-
porting. During the past several years, more nuclear radiolo-
gists are reporting this number because of the large number
of studies that have shown its clinical importance.20,21 The
differences in techniques used by various centers influence
the SUV values. Our goal is for the maxSUV at one center
to have the same ‘‘oncologic clinical meaning’’ as the max-
SUV at another center and for the values to be universally
translatable. However, this has not come to fruition. Because
the formula has only 3 variables, one would think this goal
should be easy to accomplish. The formula for the maxSUV
has 3 variables. One variable is the activity at a pixel, which
should be universally reproducible at all centers on the basis
of the software used to calculate it. The second variable is the
TABLE 2. Change in the maximum standardized uptake value of
biopsy-proven metastatic esophageal lymph nodes based on
pathologic response
Type of pathologic response
of lymph node
No.
patients
% change in maxSUV,
median (range)
Benign after neoadjuvant
chemoradiotherapy
11 73% (–16% to –100%)
Recalcitrant nodal disease 5 45% (þ24% to –100%)
maxSUV, maximum standardized uptake value.608 The Journal of Thoracic and Cardiovascular Supatient’s weight, which also should be globally reproducible.
The third variable is the injected dose of FDG. This variable
may be the most difficult to standardize because the entire
dose of FDG may not be given intravenously and the wells
that calibrate the amount of FDG given may not be accurate.
Finally, other variables make the maxSUV different at vari-
ous centers, for example, the time between the completion of
the injected FDG and the scanning, and the patient’s glucose
level at the time of the scan.We believe these differences will
be slowly resolved; however, for now the maxSUV from one
center is too different from the maxSUV at another center.
For these reasons, we mandated that the initial and repeat
PET be performed at the same center.
Limitations and Strengths
Limitations of the study include the following: a) its retro-
spective nature; b) only 86 of the 221 Ivor Lewis esophago-
gastrectomies were included in the analysis because many
patients did not receive neoadjuvant therapy, standardized
uptake values were not reported, or patients did not have
both the initial and the repeat PET scans at the same center;
and c) an accuracy of only approximately 75%, as suggested
by the area under the curve in Figure 1. Strengths of the
study include the following: a) stringent entry criteria; b)
the study was performed on a consecutive series of patients;
c) patients underwent surgery within 40 days of the repeat
PET scan; d) all patients had their initial and repeat PET
scans performed at the same center; e) all patients had an
Ivor Lewis esophagogastrectomy, and thus their lymph
nodes were removed in addition to the esophagus (some
patients have pT0N1disease); and f) the consistent timing
between the last dose of the neoadjuvant chemoradiotherapy
and the repeat PET scan. Our previous study for repeat im-
aging for NSCLC showed that PET was most efficacious
when repeated at 4 weeks after the last dose of neoadjuvant
therapy.5 Studies show that repeat PET at a shorter duration
may result in a low negative predictive value. Mamede and
colleagues22 performed PET scans at 22.3 14.5 days from
completion of treatment and observed a low negative predic-
tive value because of inflammation (41%–83%). Swisher
and colleagues23 performed PET scans between 21 and 35
days from completion of treatment and again noted the dif-
ficulty in differentiating inflammation from residual tumor
when PET was performed too soon after completion of radi-
ation. In 2007, Kim and colleagues24 performed PET scans
between 14 and 21 days and reported many false-positive
specimens.
CONCLUSIONS
This retrospective study showed that when initial and re-
peat PET scans are performed at the same center at least 30
days after the completion of preoperative chemoradiother-
apy, the percent change in the maxSUV is a predictor ofrgery c March 2009
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ageal cancer. When the maxSUV decreases by 64% or
more, it is likely that the patient is a complete responder.
These data may help identify patients for a future random-
ized study that compares observation with surgical resection
in patients with esophageal cancer who appear to be com-
plete responders. However, until that study is completed,
our preference remains surgical resection for the complete
responder.
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